Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon alpha-2a - Ainos/Hayashibara

Drug Profile

Interferon alpha-2a - Ainos/Hayashibara

Alternative Names: IFN-alpha lozenges; MOR 22; Natural human lymphoblastoid interferon-alpha; Veldona

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hayashibara
  • Developer Ainos; CytoPharm; Hayashibara; Mochida Pharmaceutical; NOBEL ILAC; Otsuka Pharmaceutical
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunomodulators; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polycythaemia vera; Human papillomavirus infections; Behcet's syndrome
  • New Molecular Entity No
  • Available For Licensing Yes - Behcet's syndrome; Common cold; Influenza virus infections; Sjogren's syndrome

Highest Development Phases

  • Marketed Hepatitis B; Hepatitis C; Myeloid leukaemia; Renal cell carcinoma
  • Phase III Sjogren's syndrome
  • Phase II Influenza virus infections
  • Preclinical COVID 2019 infections
  • No development reported Behcet's syndrome; Human papillomavirus infections; Solid tumours; Thrombocytopenia
  • Discontinued Chronic obstructive pulmonary disease; Fibromyalgia; HIV infections; Liver cancer; Polycythaemia vera; Pulmonary fibrosis; Skin disorders; Thrombocytosis

Most Recent Events

  • 19 Sep 2023 Ainos plans a phase III trial in Human papillomavirus infections
  • 18 Sep 2023 Ainos plans to hold a pre-IND meeting with the US FDA in advance of planned phase III clinical studies of Interferon alpha-2a for Human papillomavirus infections
  • 18 Sep 2023 Interferon alpha-2a - Ainos/Hayashibara receives Orphan Drug status for Human papillomavirus infections in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top